Pearl Bio utilizes genome and ribosome engineering to create novel biomaterials with customizable properties for smart biologics. This technology addresses the limitations of traditional biologics by enabling the production of materials with diverse chemistries that were previously unattainable.
Funding
$4.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional methods for producing biomaterials often lack the precision and diversity needed to create biologics with tailored properties. This limitation hinders the development of advanced therapies and materials with diverse chemistries.
Solution
Pearl Bio leverages a proprietary technology platform that integrates genome and ribosome engineering to produce novel biomaterials. This platform enables the creation of template-directed biomaterials with tunable properties and diverse chemistries previously unattainable. By uniting the precision of biology with chemical diversity, Pearl Bio facilitates the design and manufacture of smart biologics with customizable functionalities. The company's R&D platform supports both internal pipeline development and partnership opportunities, expanding the potential applications of its biomaterials.
Target Audience
Pearl Bio's primary customers are biotechnology and pharmaceutical companies seeking advanced biomaterials for therapeutic and research applications.
Features
- Integrates genome and ribosome engineering for precise control over biomaterial synthesis
- Produces template-directed biomaterials with tunable properties
- Enables the creation of diverse chemistries previously inaccessible through traditional methods
- Supports a deep internal pipeline of novel biologics
- Facilitates partnership opportunities for expanded application development